Cellectis S.A. $CLLS Shares Sold by Long Focus Capital Management LLC

Long Focus Capital Management LLC reduced its position in shares of Cellectis S.A. (NASDAQ:CLLS) by 12.6% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 4,123,262 shares of the biotechnology company’s stock after selling 594,031 shares during the quarter. Long Focus Capital Management LLC owned approximately 0.07% of Cellectis worth $11,751,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Cellectis by 228.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock worth $5,856,000 after purchasing an additional 3,284,409 shares during the period. Citadel Advisors LLC acquired a new position in shares of Cellectis in the 3rd quarter valued at about $633,000. Millennium Management LLC grew its position in shares of Cellectis by 61.9% during the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 22,080 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Cellectis during the 3rd quarter valued at about $72,000. Finally, Acadian Asset Management LLC raised its stake in Cellectis by 132.9% during the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 26,461 shares during the period. 63.90% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on CLLS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellectis in a research report on Wednesday, January 21st. Clear Str upgraded Cellectis to a “strong-buy” rating in a research note on Tuesday, December 23rd. Finally, Jefferies Financial Group initiated coverage on Cellectis in a research report on Tuesday, February 17th. They issued a “buy” rating and a $7.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cellectis presently has an average rating of “Moderate Buy” and an average target price of $6.33.

Cellectis Trading Up 2.3%

Shares of CLLS stock opened at $3.50 on Tuesday. Cellectis S.A. has a 1 year low of $1.10 and a 1 year high of $5.48. The stock has a fifty day moving average of $3.92 and a two-hundred day moving average of $3.92. The company has a current ratio of 1.49, a quick ratio of 1.49 and a debt-to-equity ratio of 0.63.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.